IDEXX Laboratories, Inc.
IDXX
$590.00
+0.89%
IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, providing in-house testing kits, benchtop analyzers, reference laboratory services, and practice management software for companion animals and livestock. The company's distinct competitive position is anchored by its integrated diagnostic ecosystem, which creates high switching costs for veterinary practices and has enabled it to consistently outgrow the underlying pet healthcare market. The current investor narrative centers on the company's ability to sustain mid-teens revenue growth amid a post-pandemic normalization in veterinary visits, with recent quarterly results and raised guidance reinforcing confidence in the durability of its growth algorithm. However, the stock has faced significant multiple compression over the past year, as investors weigh the balance between its premium valuation and the resilience of its end markets.…
IDXX
IDEXX Laboratories, Inc.
$590.00
Related headlines
Investment Opinion: Should I buy IDXX Today?
We rate IDXX as a Buy, given its accelerating revenue growth, strong margins, and analyst consensus with an average target of $707, implying 26.5% upside. The company's leadership in veterinary diagnostics and high switching costs provide a durable competitive advantage, supporting the premium valuation.
Sign up to view all
IDXX 12-Month Price Forecast
The AI assessment is bullish on IDXX, driven by strong fundamental momentum and a reasonable valuation relative to growth. The stock's recent decline has created an attractive entry point, and the company's raised guidance suggests confidence in the near-term outlook. However, the high beta and premium valuation warrant caution. If growth continues to accelerate and the company beats estimates, the stock could re-rate higher. Conversely, any signs of deceleration or macro headwinds could lead to further downside. The stance would be upgraded to high confidence if the stock breaks above $600, and downgraded to neutral if growth falls below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $707.00 and implied upside of +19.8% versus the current price.
Average Target
$707.00
0 analysts
Implied Upside
+19.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
The target price range spans from a low of $470.00 to a high of $805.00, representing a wide spread of 71% between the low and high, which signals significant uncertainty about the company's future performance. The high target of $805 implies a 44% upside from the current price and likely assumes that the company can sustain its growth acceleration and expand margins further, justifying a higher multiple. The low target of $470 suggests a 16% downside, possibly pricing in a scenario of competitive pressure, margin compression, or a broader market downturn. The wide range reflects the debate among analysts about whether IDEXX can maintain its premium valuation in the face of slowing industry growth, but the consensus remains constructive, with no recent downgrades and several firms reiterating their positive stance.
Bulls vs Bears: IDXX Investment Factors
IDEXX presents a classic growth-at-a-premium-price dilemma. The bull case is anchored by accelerating revenue growth (14.3% YoY), raised guidance, and a dominant position in veterinary diagnostics with high-margin recurring revenue. The bear case centers on a rich valuation (forward PE 33.8x, PEG 2.3x) and the stock's severe drawdown, which suggests the market is already pricing in pessimism. Currently, the bull case has stronger evidence given the fundamental momentum and analyst support, but the key tension is whether the growth acceleration can justify the premium multiple. If growth decelerates or the market turns risk-off, the stock could face further downside toward the 52-week low of $518.55.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 14.3% YoY to $1.14B, accelerating from 9.4% in Q4 2025 and 8.9% in Q2 2025, demonstrating strong momentum in veterinary diagnostics demand.
- Raised Guidance Signals Confidence: Management raised full-year guidance citing higher clinical visits and diagnostic frequency, reinforcing the durability of the growth algorithm and supporting the forward PE of 33.8x.
- High-Margin Recurring Revenue: Gross margin expanded to 63.4% in Q1 2026 (up from 60.3% in Q4 2025), with operating margin at 31.8%, reflecting strong pricing power and operating leverage.
- Strong Analyst Consensus: With a Buy rating and average target of $707 (26.5% upside), 14 analysts see further upside, and the high target of $805 implies 44% potential.
Bearish
- Premium Valuation: Trailing PE of 51.4x and forward PE of 33.8x are well above the market, and the PEG ratio of 2.3x suggests the stock is expensive even for its growth rate.
- Severe Multiple Compression: The stock is down 27.4% from its 52-week high and 16.6% over the last six months, reflecting investor concerns about valuation and slowing industry growth.
- High Beta and Macro Sensitivity: With a beta of 1.55, the stock is highly sensitive to market swings; rising interest rates or a broad market correction could pressure the multiple further.
- Dependence on Growth Sustainability: The forward PE implies ~52% EPS growth, which relies on continued acceleration; any deceleration in clinical visits or diagnostic frequency could trigger de-rating.
IDXX Technical Analysis
IDEXX's stock is in a clear downtrend over the past year, with the price declining 16.6% over the last six months and currently trading at $559.07, which is only 9.4% above its 52-week low of $518.55 and 27.4% below its 52-week high of $769.98. The 1-year price change of +4.6% masks the severe drawdown from the highs, as the stock has been in a persistent decline since early 2026, with a maximum drawdown of -31.3% from its peak. This positioning near the lower end of its 52-week range suggests that the market is pricing in significant pessimism, potentially offering a value opportunity if the fundamental thesis remains intact, but also reflecting the risk of a falling knife.
Beta
1.54
1.54x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$519-$770
Price range past year
Annual Return
-5.5%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +2.8% |
| 3m | +5.3% | +4.2% |
| 6m | -8.5% | +11.3% |
| 1y | -5.5% | +21.5% |
| ytd | -11.9% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue growth remains robust, with the most recent quarter (Q1 2026) reporting revenue of $1.1408 billion, a 14.3% year-over-year increase, accelerating from the 9.4% growth seen in Q4 2025. The multi-quarter trend shows a steady acceleration from 8.9% growth in Q2 2025 to the current 14.3%, driven by higher clinical visits and diagnostic frequency, as highlighted in the company's raised guidance. Revenue segments show a balanced mix with product sales of $666.1 million and service revenue of $474.7 million, indicating strength across both instrument sales and recurring reference lab services. This growth trajectory supports the investment case for a company that is gaining share in the veterinary diagnostics market, though the sustainability of this acceleration will be key to watch.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given IDEXX's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 51.4x, while the forward PE is 33.8x, implying that the market expects significant earnings growth of approximately 52% over the next year, which aligns with the company's raised guidance and estimated EPS of $26.10 for the current fiscal year. The gap between trailing and forward PE suggests that the market is pricing in a substantial acceleration in profitability, which is supported by the company's improving operating leverage and margin expansion. However, the PEG ratio of 2.3x indicates that the stock is not cheap even on a growth-adjusted basis, and the EV/EBITDA of 37.5x further underscores the premium valuation.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.67, which is manageable but not negligible, and a current ratio of 1.17, indicating adequate liquidity. The company's high operating margin of 31.8% provides a cushion, but any margin compression from competitive pricing or input costs could impact profitability. Cash flow is strong (FCF TTM $1.08B), but the stock's valuation leaves little room for error—if earnings growth falls short of the ~52% implied by the forward PE, the stock could de-rate sharply.